A late-stage life sciences investment partnership that leverages nearly 20 years of capital markets and clinical experience to invest in the development of breakthrough therapeutics that improve and save lives.
| Firm Name | Aisling Capital |
| Investment Thesis | A late-stage life sciences investment partnership that leverages nearly 20 years of capital markets and clinical experience to invest in the development of breakthrough therapeutics that improve and save lives. |
| City | New York |
| Founded | 2000 |
| Number of Team Members | 8 investment professionals |
| Investment Stage | Late-stage clinical opportunities - invests in companies with drugs in fairly advanced stages of research |
| Founding/Managing Partners | Steven Elms (Managing Partner) and Andrew Schiff, MD (Managing Partner) |
| Legal Entity | Aisling Capital LLC (registered investment advisor with U.S. SEC) |
| Contact Email | jhoerrner@aislingcapital.com |